
Shaily Engineering Plastics Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- Pharma segment expected to grow at 50%-60% in the current year (FY '25).
- Overall volume of pens/devices anticipated to increase from ~11 million in FY '24 to around 17-18 million in FY '25, reflecting 15%-16% growth.
- Capacity utilization currently around 40%, expected to increase as new business scales up.
- Plans to ramp up pen/device volumes gradually with approvals on proprietary platforms like Teriparatide and Liraglutide anticipated in FY '25.
- Additional capex of $15-$20 million planned over the next 6-7 years to expand capacity from current 25-30 million devices per year to ~60-70 million.
- Revenue growth expected from increasing proportion of proprietary devices (currently shifting from 10% to ~30-40% of value).
- Consumer segment faced a degrowth of ~4% due to raw material pass-through and lower toy sales but base business expected to grow 12%-15%.
- Shaily UK revenue to be back-ended with more growth expected in H2 FY '25.
See what Shaily Engineering Plastics management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- There is no expectation for significant new fundraising through debt or equity in the near term.
- The company has already made a substantial capex investment last year, creating infrastructure to handle production capacity up to 60-70 million devices annually.
- Additional capex of $15-20 million may be needed to scale from 25-30 million to 70 million devices, but this is planned over the next 6-7 years, not the next 2-3 years.
- The management does not foresee the need for large-scale fundraising (e.g., $50-100 million) for semaglutide or other programs.
- The focus is on improving capacity utilization and organic growth rather than immediate capital raising.
- No substantial capex or capital raising is planned for FY25; only minor capex will be undertaken to improve utilization.
See what Shaily Engineering Plastics management said on order book — free account, 30 seconds.
Capex plans
Yes- No substantial capex is planned immediately; only small capexes are expected in FY25.
- Focus currently is on improving utilization of existing capacity rather than large new investments.
- A previous large capex was done last year to create infrastructure supporting up to 60-70 million devices annually.
- Installed equipment currently supports 25-30 million devices per year; additional machinery will be added as approvals and scale-up occur.
- Future additional capex of around $15-20 million may be required to expand capacity from 30 million to 70 million devices, but this is not expected within the next 2-3 years; envisioned over 6-7 years.
- Capex for semaglutide-related scale-up is expected to be lower due to location in India and existing infrastructure.
- The company is managing growth and capacity expansion prudently without aggressive capital investment in the near term.
Track Shaily Engineering Plastics — get its next earnings analysis in your feed
How does Shaily Engineering Plastics rank vs peers in Consumer Durables?
Pro featureHow does Shaily Engineering Plastics rank in Consumer Durables?
Compare Shaily Engineering Plastics against every Consumer Durables company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Shaily Engineering Plastics's management said in earlier quarters
Others in Consumer Durables this season
- Arham Tech (Q2 FY27)
Revenue from Operations for H1FY27: ₹85.48 Crores, an 87.34% year-on-year increase from ₹45.63 Crores in H1FY26 (Page 30, 29). Key investor presentation takeawa
- Khazanchi Jewell (Q2 FY27)
Q2 FY27 revenue from operations: ₹605.58 Crore, up 10.4% YoY (Q2 FY26: ₹548.60 Crore) [Page 7] . Key investor presentation takeaways from Khazanchi Jewellers Lt
- Uday Jewellery (Q2 FY27)
Q2 FY27 Total Income: ₹210.46 crore, up 30% year-on-year (YoY) . Key results statement takeaways from Uday Jewellery Industries Ltd's Q2 FY27 results statement
- Rajesh Exports (Q2 FY27)
Revenue from operations (net sales) for the quarter ended 30/09/2026: ₹2,895.85 million. Key results statement takeaways from Rajesh Exports Ltd's Q2 FY27 resul